14th edition

Format
HYBRID

December 2nd & 3rd, 2025

IN-PERSON | STRASBOURG

December 8th ,2025

ONLINE MEETINGS

Stand

2020 Edition

StemSight

Finland

We are commercializing a treatment for a severe form of corneal blindness called limbal stem cell deficiency. This rare disease causes a significant societal burden because it occurs especially in young and working age people. The treatment is based on IP-protected technology for differentiating highly potent limbal stem cells from human pluripotent stem cells, providing an unlimited source of therapeutic cells. Our technology is currently in the preclinical phase.

Scroll to Top
  • No products in the cart.